EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia

By: via Benzinga
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO® ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.